rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy

These findings have high clinical relevance since they define rs10204525 binding to miR-4717-3p-mediated PD-1 expression and induction as a mechanism modulating the reactivity of immune cells to non-cancer cells as well as a novel biomarker for predicting irAEs in patients with advanced cancer treated with anti-PD-1/PD-L1-based immunotherapy.

Authors

Institutions

Publication Details

Journal
Journal for ImmunoTherapy of Cancer
Published
2025-12-01
DOI
https://doi.org/10.1136/jitc-2025-012207
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy

Emanuela De Bellis, Francesco Sabbatino, Giovanna Polcaro, Valeria Conti et al.
Journal for ImmunoTherapy of Cancer
Cancer Immunotherapy and Biomarkers
article

rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy

Emanuela De Bellis, Francesco Sabbatino, Giovanna Polcaro, Valeria Conti, Maddalena Langella, Luigi Liguori, Marco Cascella, Berenice Stefanelli, Valentina Manzo, Cristina R. Ferrone, Stefano Pepe, Alessandro Ottaiano, Alessandro Caputo, Amelia Filippelli, Valentina Pagliara, Rosanna Martinelli
article en

Abstract

These findings have high clinical relevance since they define rs10204525 binding to miR-4717-3p-mediated PD-1 expression and induction as a mechanism modulating the reactivity of immune cells to non-cancer cells as well as a novel biomarker for predicting irAEs in patients with advanced cancer treated with anti-PD-1/PD-L1-based immunotherapy.

Journal for ImmunoTherapy of CancerVol. 13(12)
Cedars-Sinai Medical Center (US), University of Salerno (IT), Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona (IT), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Openalex Percentile: Top 47%
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

rs10204525 binding to miR-4717-3p modulates PD-1 expression and predicts the development of immune-related adverse events in patients with advanced cancer treated with anti-PD-1/PD-L1 therapy — Emanuela De Bellis, Francesco Sabbatino, et al. · Journal for ImmunoTherapy of Cancer (2025) | TGRS Research Map | TGRS